Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis
ObjectiveThe prevalence of long COVID among cancer patients remains unknown. This study aimed to determine the prevalence of long COVID and explore potential risk factors among cancer patients.MethodsA systematic search was performed on PubMed, Web of Science, and Embase from database inception unti...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1506366/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527942145900544 |
|---|---|
| author | Hongkun Xu Hongkun Xu Tingting Lu Yajie Liu Jingqi Yang Simeng Ren Baojin Han Honghao Lai Long Ge Jie Liu |
| author_facet | Hongkun Xu Hongkun Xu Tingting Lu Yajie Liu Jingqi Yang Simeng Ren Baojin Han Honghao Lai Long Ge Jie Liu |
| author_sort | Hongkun Xu |
| collection | DOAJ |
| description | ObjectiveThe prevalence of long COVID among cancer patients remains unknown. This study aimed to determine the prevalence of long COVID and explore potential risk factors among cancer patients.MethodsA systematic search was performed on PubMed, Web of Science, and Embase from database inception until 21 March 2024, to identify studies that reported long COVID in cancer patients. Two investigators independently screened the studies and extracted all information about long COVID in cancer patients for subsequent analysis. Methodological quality was assessed using the “Joannagen Briggs Institute (JBI) Critical Appraisal Checklist for Studies Reporting Prevalence Data”.ResultsA total of 13 studies involving 6,653 patients were included. The pooled prevalence of long COVID was 23.52% [95% confidence interval (CI), 12.14% to 40.64%] among cancer patients reported experiencing long COVID after acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The pooled prevalence of any long COVID in cancer patients was 20.51% (95% CI, 15.91% to 26.03%), 15.79% (95% CI, 11.39% to 21.47%), and 12.54% (95% CI, 6.38% to 23.18%) in 3, 6, and 12 months follow-up duration. Fatigue was the most common symptom, followed by respiratory symptoms, myalgia, and sleep disturbance. Patients with comorbidities had a significantly higher risk of experiencing long COVID [odds ratio (OR) = 1.72; 95% CI, 1.09 to 2.70; p = 0.019]. No statistically significant differences in sex, primary tumor, or tumor stage were detected.ConclusionNearly a quarter of cancer patients will experience long COVID after surviving from SARS-CoV-2 infection, and this would even last for 1 year or longer. Fatigue, respiratory symptoms, myalgia, and sleep disturbance need to be more addressed and managed to reduce symptom burden on cancer patients and improve quality of life. Patients with comorbidities are at a high risk of developing long COVID. Further randomized controlled trials with rigorous methodological designs and large sample sizes are needed for future validation.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023456665. |
| format | Article |
| id | doaj-art-ed1f0de5fe104ac99eec87f29fba6ae7 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ed1f0de5fe104ac99eec87f29fba6ae72025-01-15T05:11:08ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.15063661506366Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysisHongkun Xu0Hongkun Xu1Tingting Lu2Yajie Liu3Jingqi Yang4Simeng Ren5Baojin Han6Honghao Lai7Long Ge8Jie Liu9Graduate School, Beijing University of Chinese Medicine, Beijing, ChinaGuang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaGuang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaGuang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGuang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaEvidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, ChinaEvidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, ChinaGuang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaObjectiveThe prevalence of long COVID among cancer patients remains unknown. This study aimed to determine the prevalence of long COVID and explore potential risk factors among cancer patients.MethodsA systematic search was performed on PubMed, Web of Science, and Embase from database inception until 21 March 2024, to identify studies that reported long COVID in cancer patients. Two investigators independently screened the studies and extracted all information about long COVID in cancer patients for subsequent analysis. Methodological quality was assessed using the “Joannagen Briggs Institute (JBI) Critical Appraisal Checklist for Studies Reporting Prevalence Data”.ResultsA total of 13 studies involving 6,653 patients were included. The pooled prevalence of long COVID was 23.52% [95% confidence interval (CI), 12.14% to 40.64%] among cancer patients reported experiencing long COVID after acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The pooled prevalence of any long COVID in cancer patients was 20.51% (95% CI, 15.91% to 26.03%), 15.79% (95% CI, 11.39% to 21.47%), and 12.54% (95% CI, 6.38% to 23.18%) in 3, 6, and 12 months follow-up duration. Fatigue was the most common symptom, followed by respiratory symptoms, myalgia, and sleep disturbance. Patients with comorbidities had a significantly higher risk of experiencing long COVID [odds ratio (OR) = 1.72; 95% CI, 1.09 to 2.70; p = 0.019]. No statistically significant differences in sex, primary tumor, or tumor stage were detected.ConclusionNearly a quarter of cancer patients will experience long COVID after surviving from SARS-CoV-2 infection, and this would even last for 1 year or longer. Fatigue, respiratory symptoms, myalgia, and sleep disturbance need to be more addressed and managed to reduce symptom burden on cancer patients and improve quality of life. Patients with comorbidities are at a high risk of developing long COVID. Further randomized controlled trials with rigorous methodological designs and large sample sizes are needed for future validation.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023456665.https://www.frontiersin.org/articles/10.3389/fonc.2024.1506366/fullcancerCOVID-19long COVIDprevalencerisk factors |
| spellingShingle | Hongkun Xu Hongkun Xu Tingting Lu Yajie Liu Jingqi Yang Simeng Ren Baojin Han Honghao Lai Long Ge Jie Liu Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis Frontiers in Oncology cancer COVID-19 long COVID prevalence risk factors |
| title | Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis |
| title_full | Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis |
| title_fullStr | Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis |
| title_full_unstemmed | Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis |
| title_short | Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis |
| title_sort | prevalence and risk factors for long covid among cancer patients a systematic review and meta analysis |
| topic | cancer COVID-19 long COVID prevalence risk factors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1506366/full |
| work_keys_str_mv | AT hongkunxu prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis AT hongkunxu prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis AT tingtinglu prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis AT yajieliu prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis AT jingqiyang prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis AT simengren prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis AT baojinhan prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis AT honghaolai prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis AT longge prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis AT jieliu prevalenceandriskfactorsforlongcovidamongcancerpatientsasystematicreviewandmetaanalysis |